Optimization of antiaggregant therapy in rheumatoid arthritis and coronary heart disease patients receiving nonsteroidal anti-inflammatory drugs

Objective: to study coagulative and vascular-thrombocytic hemostases in patients with rheumatoid arthritis (RA) and coronary heart disease (CHD) depending on therapy with different nonsteroidal anti-inflammatory drugs (NSAIDs) alone and in combination with low-dose aspirin. Subjects and methods. The trial enrolled 58 patients (43 women and 15 men) with a valid diagnosis of RA. The patients' mean age was 61.2 years; the disease duration averaged 10 years. All the patients received therapy with disease-modifying antirheumatic drugs (DMARDs) and NSAIDs. All had CHD; 52 of the 58 patients presented with arterial hypertension; 30 had noncoronary atherosclerosis. Cardiovascular diseases were first identified in 18 patients. All took heart medications. Coagulative and vascular-thrombocytic hemostases were studied in all the patients and the results were compared depending on to the taken NSAID (diclofenac, tenoxicam, nimesulide, meloxicam). Thirty-seven patients who had not previously received antiaggregant therapy were given aspirin in a dose of 100 mg when they were found to have platelet hyperaggregation and aggregation was restudied on aspirin therapy days 7-8. A control group consisted of 26 healthy men (mean age 55 years) who received no medications. Results. In patients with RA and CHD, activated coagulative hemostasis was identified in 65.5% of cases. The signs of hypercoagulation were observed in 35 of the 58 patients. When different NSAIDs were used, the coagulative hemostatic changes were unidirectional and no statistically significant differences were found between the groups. The patients taking diclofenac, nimesulide, or meloxicam were found to have activated vascular-thrombocytic hemostasis. Those receiving tenoxicam showed a tendency towards decreased adrenaline-induced platelet aggregation (the drug's aspirin-like effect); however, no statistical processing was made because of few cases. The use of aspirin in the patients taking diclofenac, nimesulide, or meloxicam resulted in lower platelet aggregation in the vast majority of cases despite NSAID intake. No adequate aspirin response was obtained in 32.4% of the patients. Conclusion. Aspirin is indicated in RA and CHD patients receiving NSAIDS. Antiaggregant therapy should be used under control of vascular-thrombotyc hemostasis as aspirin is insufficiently effective in one third of cases in this group.

rheumatoid arthritis, coronary heart disease, nonsteroidal anti-inflammatory drugs, platelet aggregation

1. <div><p>Попкова Т.В., Новикова Д.С., Насонов Е.Л. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: Клинические рекомендации. М.: ГЭОТАР-Медиа, 2010;678-702.</p><p>Peters M.J., Symmons D.P., McCarey D.W. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis - TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis 2010;69(2):325-31.</p><p>Насонов Е.Л., Попкова Т.В. Кардиоваскулярные проблемы ревматологии. Науч-практич ревматол 2004;4:4-9.</p><p>Goodson N.I., Willes N.J., Lunt N.C. Mortality on early inflammatory arthritis: cardiovascular mortality in seropositive patients. Arthr Rheum 2002;46:2010-9.</p><p>Gonzalez-Gay M.A., Gonzalez-Juanatey C., Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthr Rheum 2005;35: 8-17.</p><p>Gerli R., Bartoloni Bocci E., Sherer Y. et al. Association of anticyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:724-5.</p><p>Lopes-Longo FJ., Oliver-Minnaro D., de la Torre I. et al. Association between anticyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthr Rheum 2009;61:419-24.</p><p>Maradit-Kremers H., Crowson C.S., Nicola PJ. et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthr Rheum 2005;52:402-11.</p><p>Maradit-Kremers H., Nicola PJ., Crowson C.S. et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthr Rheum 2005;52:722-32.</p><p>Ананьева Н. Механизмы формирования тромба при атеросклерозе. Тромбоз, гемостаз и реология 2002;2:10-5.</p><p>Васильева Е.Ю. Состояние тромбоцитарно-эндотелиального гемостаза и липидного обмена у больных с различными клинико-патогенетическими формами стенокардии. В кн.: Проблемы физиологии и патологии системы гемостаза. Под ред. А.И. Воробьева, Е.И. Буевича. Барнаул: Академический центр диагностики и лечения нарушений гемостаза СО РАМН, 2000; 231.</p><p>Саидов Е.У. Состояние свертывающей системы крови и микроциркуляторного кровотока у больных ревматоидным артритом. Материалы Российского национального конгресса кардиологов «Повышение качества и доступности кардиологической помощи». М., 2008; 151.</p><p>Фатхуллина Г.Ф., Камалова Р.Г. Оценка фактора Виллебранда у больных ревматоидным артритом. Матер. IV съезда ревматологов России. Казань, 2005; 54 с.</p><p>Arnett F.C., Edworty S.M., Bloch D.A. The ARA 1987 revised criteria for classification of rheumatoid arthritis. Arthr Rheum 1988;31:315-24.</p><p>Ревматология: Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008;168 с.</p><p>Кардиология: Национальное руководство. Под ред. Ю.Н. Беленкова, Р.Г. Оганова. М.: ГЭОТАР-Медиа, 2007.</p><p>Ruggeri Z.M. Von Willebrand factor, platelets and endothelial cell interaction. Thromb Haemost 2003;1(7):1335-42.</p><p>Adams R.J., Cyimowitz M.I., Alpert J.S. et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association, American Stroke Association. Stroke 2007;38(5):1655-711.</p><p>Patrono C., Coller B., Dalen J.E. et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119:39-63.</p><p>Wienecke T., Gotzche P. Paracetamol versus nonsteroidal anti-inflammatory drug for rheumatoid arthritis. Cochrane Library 2004; CD003789.</p><p>Garner S., Fidan D., Frankish R. et al. Celecocsib for rheumatoid arthritis. Cochrane database Syst Rev 2004; CD003789.</p><p>Trelle S., Reichenbach S., Wandel S. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.</p><p>Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. М.: ИМА-ПРЕСС, 2009.</p><p>Попкова Т.В., Новикова Д.С., Насонов Е.Л. Рекомендации по снижению кардиоваскулярного риска у пациентов с воспалительными артритами (по материалам рекомендаций Европейской антиревматической лиги). Совр ревматол 2010;1:7-11.</p><p>Strand V. Are COX-2 inhibitor preferable to non-selective nonsteroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007;370(9605): 2138-51</p><p>Насонов Е.Л. Специфические ингибиторы ЦОГ-2: решенные и нерешенные проблемы. Клин фармакол тер 2000;1:57-64.</p><p>Fitzgerald G., Patrono C. The coxibs, selective inhibitor of cyclooxygenase-2. New Engi J Med 2001;345:433-42</p><p>Насонов Е.Л. Нестероидные противовоспалительные препараты: новые аспекты применения в ревматологии и кардиологии. Рус мед журн. Ревматология 2003;11(23):1280-4.</p><p>Howard PA. Aspirin resistance. Ann Pharmacoter 2002;36:1620-4.</p><p>Gum P.A., Kottke-Marchant K., Poggio Ed. et al. Profile and prevalence of aspirin resistence in patients with cardiovascular disease. Am J Cardiol 2001;88:230-4.</p><p>Weber A.A., Zimmermann K.C., Meyer-Kirchath J., Schor K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistence. Lancet 1999;353:900.</p><p>ChenW.-H., Lee P.Y., Ng W. et al. Prevalence, profile, and predictors of aspirin resistance measured by the Ultegra rapid platelet function assay-ASA in patients with coronary artery disease. J Am Coll Cardiol 2005;45:382A.</p><p>Wang T.H., Bhatt D.L., Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006;27:647-54.</p></div><br />